CN112437683A - 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物 - Google Patents

用作白细胞介素-1 活性抑制剂的磺酰脲类化合物 Download PDF

Info

Publication number
CN112437683A
CN112437683A CN201980048411.9A CN201980048411A CN112437683A CN 112437683 A CN112437683 A CN 112437683A CN 201980048411 A CN201980048411 A CN 201980048411A CN 112437683 A CN112437683 A CN 112437683A
Authority
CN
China
Prior art keywords
radical
group
alkyl
pharmaceutically acceptable
membered heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048411.9A
Other languages
English (en)
Chinese (zh)
Inventor
J·A·斯塔福德
J·M·维尔
L·L·特佐斯
C·麦克布赖德
R·M·帕斯托尔
S·T·斯塔本
C·斯蒂瓦拉
M·沃尔格拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN112437683A publication Critical patent/CN112437683A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201980048411.9A 2018-07-20 2019-07-19 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物 Pending CN112437683A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20
US62/701,358 2018-07-20
PCT/US2019/042703 WO2020018970A1 (en) 2018-07-20 2019-07-19 Sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (1)

Publication Number Publication Date
CN112437683A true CN112437683A (zh) 2021-03-02

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048411.9A Pending CN112437683A (zh) 2018-07-20 2019-07-19 用作白细胞介素-1 活性抑制剂的磺酰脲类化合物

Country Status (20)

Country Link
US (1) US11560391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823726A1 (cg-RX-API-DMAC7.html)
JP (1) JP7411631B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034588A (cg-RX-API-DMAC7.html)
CN (1) CN112437683A (cg-RX-API-DMAC7.html)
AR (1) AR117617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019305095A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001012A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000817A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210024A (cg-RX-API-DMAC7.html)
IL (1) IL280139A (cg-RX-API-DMAC7.html)
MA (1) MA53170A (cg-RX-API-DMAC7.html)
MX (1) MX2021000660A (cg-RX-API-DMAC7.html)
PE (1) PE20211049A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552155A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012159TA (cg-RX-API-DMAC7.html)
TW (1) TW202019937A (cg-RX-API-DMAC7.html)
WO (1) WO2020018970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
CA3252822A1 (en) 2022-02-21 2023-08-24 Viva Star Biosciences (Suzhou) Co., Ltd. NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN122555708A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
CN122555707A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
WO2018136890A1 (en) * 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428696A (zh) * 2015-02-16 2017-12-01 昆士兰大学 磺酰脲和相关化合物及其用途
WO2018136890A1 (en) * 2017-01-23 2018-07-26 Jecure Therapeutics, Inc. Chemical compounds as inhibitors of interleukin-1 activity

Also Published As

Publication number Publication date
IL280139A (en) 2021-03-01
EP3823726A1 (en) 2021-05-26
SG11202012159TA (en) 2021-01-28
CR20210024A (es) 2021-02-22
CA3104199A1 (en) 2020-01-23
BR112021001012A2 (pt) 2021-04-20
CO2021000817A2 (es) 2021-02-17
US20210261568A1 (en) 2021-08-26
KR20210034588A (ko) 2021-03-30
PE20211049A1 (es) 2021-06-04
JP7411631B2 (ja) 2024-01-11
AU2019305095A1 (en) 2020-12-17
US11560391B2 (en) 2023-01-24
TW202019937A (zh) 2020-06-01
PH12020552155A1 (en) 2021-07-05
CL2021000152A1 (es) 2021-07-09
AR117617A1 (es) 2021-08-18
JP2021530536A (ja) 2021-11-11
MX2021000660A (es) 2021-03-25
WO2020018970A1 (en) 2020-01-23
MA53170A (fr) 2021-05-26

Similar Documents

Publication Publication Date Title
JP7411631B2 (ja) インターロイキン-1活性の阻害剤としてのスルホニル尿素化合物
TWI825134B (zh) 作為介白素-1活性之抑制劑之磺醯脒(sulfonimidamide)化合物
JP6924267B2 (ja) ピロロ[1,2−b]ピリダジン誘導体
US8545897B2 (en) Pyrrolopyridines as kinase inhibitors
CN107074867B (zh) 作为jak抑制剂的氨基嘧啶基化合物
CN111936486A (zh) 用作IL-12、IL-23和/或IFNα响应的调节剂的包含吡啶的杂环化合物
JP2023510918A (ja) Map4k1阻害剤
CN114716381A (zh) 可用作激酶抑制剂的化合物
JP2023524167A (ja) Nav1.8阻害剤としての2-オキソイミダゾリジン-4-カルボキサミド
JP2023542205A (ja) 新規化合物
HK40040939A (en) Sulfonylurea compounds as inhibitors of interleukin-1 activity
RU2820289C2 (ru) Соединения сульфонимидамида в качестве ингибиторов активности интерлейкина-1
HK40042117A (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
HK40097906A (en) Compounds, compositions, and methods
HK1145841A (en) Heteroaryl amide analogues as p2x7 antagonists

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040939

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination